Patents by Inventor Torben Lauesgaard Nissen
Torben Lauesgaard Nissen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160222365Abstract: The invention relates to a variant of a parent Termamyl-like ?-amylase, which exhibits an alteration in at least one of the following properties relative to said parent ?-amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60° C.Type: ApplicationFiled: February 1, 2016Publication date: August 4, 2016Applicant: NOVOZYMES A/SInventors: Torben Vedel Borchert, Allan Svendsen, Carsten Andersen, Bjarne Nielsen, Torben Lauesgaard Nissen, Soren Kjaerulff
-
Publication number: 20140248685Abstract: The invention relates to a variant of a parent Termamyl-like ?-amylase, which exhibits an alteration in at least one of the following properties relative to said parent ?-amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60° C.Type: ApplicationFiled: January 24, 2014Publication date: September 4, 2014Applicant: NOVOZYMES A/SInventors: Torben Vedel Borchert, Allan Svendsen, Carsten Andersen, Bjarne Nielsen, Torben Lauesgaard Nissen, Soren Kjaerulff
-
Publication number: 20140017715Abstract: The invention relates to a variant of a parent Termamyl-like ?-amylase, which exhibits an alteration in at least one of the following properties relative to said parent ?-amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60° C.Type: ApplicationFiled: March 5, 2013Publication date: January 16, 2014Applicant: NOVOZYMES A/SInventors: Torben Vedel Borchert, Allan Svendsen, Carsten Andersen, Bjarne Nielsen, Torben Lauesgaard Nissen, Soren Kjaerulff
-
Publication number: 20110020266Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: ApplicationFiled: February 18, 2010Publication date: January 27, 2011Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7696153Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: April 13, 2010Assignee: Maxygen, Inc.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Publication number: 20090263881Abstract: The invention relates to a variant of a parent Termamyl-like ?-amylase, which exhibits an alteration in at least one of the following properties relative to said parent ?-amylase: i) improved pH stability at a pH from 8 to 10.5; and/or ii) improved Ca2+ stability at pH 8 to 10.5, and/or iii) increased specific activity at temperatures from 10 to 60° C.Type: ApplicationFiled: December 10, 2007Publication date: October 22, 2009Applicant: Novozymes A/SInventors: Torben Vedel Borchert, Allan Svendsen, Carsten Andersen, Bjarne Nielsen, Torben Lauesgaard Nissen, Soren Kjaerulff
-
Patent number: 7550566Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: June 23, 2009Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7550565Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: June 23, 2009Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7541163Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: August 14, 2007Date of Patent: June 2, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse
-
Patent number: 7541436Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: May 4, 2007Date of Patent: June 2, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Patent number: 7537755Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: August 15, 2007Date of Patent: May 26, 2009Assignees: Maxygen, Inc., Roche Palo Alto LLCInventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Patent number: 7531630Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: September 13, 2006Date of Patent: May 12, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
-
Patent number: 7531324Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: September 13, 2006Date of Patent: May 12, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Roberto Falkenstein
-
Patent number: 7504097Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: October 30, 2006Date of Patent: March 17, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Patent number: 7498152Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: October 30, 2006Date of Patent: March 3, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Publication number: 20090042252Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: October 30, 2006Publication date: February 12, 2009Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Patent number: 7488473Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: October 30, 2006Date of Patent: February 10, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Patent number: 7488801Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: October 30, 2006Date of Patent: February 10, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Patent number: 7488589Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: GrantFiled: October 30, 2006Date of Patent: February 10, 2009Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
-
Publication number: 20090017501Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.Type: ApplicationFiled: October 30, 2006Publication date: January 15, 2009Inventors: Phillip A. Patten, Sridhar Govindarajan, Sridhar Viswanathan, Torben Lauesgaard Nissen
